Zug, Switzerland - Devirex AG "Devirex" or "the Company" since its foundation in 2006 by two Swiss chemists has continuously and sustainably built up and expanded its market position. The formula, appearance and packaging of lipivir(R), a lip gel for the prevention of cold sores (herpes simplex virus, HSV-1), were tested in the UK for over a year. Now the product launch is to take place in Switzerland and Austria. Devirex is entering a new planning phase: what was created in a laboratory will gradually be supplied to various markets. After hundreds of hours of development, research, and analysis, lipivir(R) lip gel, which prevents cold sores, will be available in Switzerland and Austria in pharmacies, drugstores, beauty spas and online as early as autumn 2021. The Swiss home market enjoys great prestige and poses its own challenges in view of the language differences, for which Devirex is well prepared. The experience and knowledge required for this comes from extensive market research conducted over several years in the Swiss, German, UK, French, Hong Kong and Singapore markets. The product launch in the UK market now allows Devirex to pursue an intensive expansion strategy. Accordingly, Devirex intends to be present the lipivir product in the markets of the entire European Union as well as the Asia-Pacific region. The European Union alone has a target market of around 500 million consumers with purchasing power, while the Asia-Pacific region has a further 2.1 billion consumers. Devirex intends to use this enormous catchment area, with increasing purchasing power in the middle class, to build up and expand the launch of lipivir(R). The decision to sell lipivir(R) online in the majority of markets is based on the fact that these markets are very strongly developed online and thus the promotion via online channels can be planned in a target group-affine and highly cost-efficient way. The potential of lipivir(R) is obvious: while conventional cold sore products treat the outbreak of herpes, lipivir(R) prevents a possible outbreak thanks to its unique formula. Lipivir(R) is not only better than other products, but uniquely different. The approved composition of lipivir(R) helps prevent cold sores and protects the sensitive skin. The lip gel lipivir(R) can be used together with cosmetics and is positioned predominantly in the core target group "women, 25-45 years" as a care product that serves the prophylaxis of lip herpes, comparable to anti-wrinkle creams, skin care products or healthy nutrition. As an approved medical device, lipivir is not subject to compulsory medication and can be sold over-the-counter without a prescription or medical advice.lipivir(R), the innovation for the prevention of herpes blisters.lipivir.com
The Swiss company Devirex AG, based in the canton of Zug, owns the patents and trademark rights to the lip gel lipivir(R), which prevents the outbreak of lip herpes when used regularly. The medicinal gel is applied to the lip area daily in the morning and evening and can easily be combined with other lip care products. Lipivir(R) is available online in France, Italy, Austria, Switzerland and the UK at www.lipivir.com
.The patents and trademark rights for lipivir(R) are registered in the following countries: Canada, China, EU, Hong Kong, Israel, Japan, Mexico, Russia, Singapore, South Africa, South Korea, Turkey, USA.Patent Attorney: Mewburn Ellis (London)Devirex AG Blegistrasse 1 CH-6343 Rotkreuz Switzerland T +41 41 758 00 00 firstname.lastname@example.org?www.devirex.ch devirex.com
? End of Media Release Issuer: Devirex AG Key word(s): Health
19.07.2021 Dissemination of a Press Release, transmitted by EQS Group - a company of EQS Group AG.The issuer is solely responsible for the content of this announcement.
Language: English Company: Devirex AG Blegistrasse 1 6343 Rotkreuz
Switzerland Phone: +41 417580000 E-mail: email@example.com Internet: devirex.ch EQS News ID: 1219883 ? End of News EQS Group Media